Evaluation of anti-tumor property of specific and non-specific BRM's in experimental glioma by assessing the microglial cell functional and phenotypic modulations

Cancer Biology and Therapy

Volumn 2, Issue 4, 2003, Pages 356-363

  Begum, Zarina ^a   Sarkar, Susobhan ^a   Mukherjee, Joydeep ^a   Ghosh, Anirban ^a   Chaudhuri, Samares ^b   Chaudhuri, Swapna ^a  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Biological response modifier (BRM); Brain tumor; Immunotherapy; Microglia; Microglial functional alterations; Microglial receptor modulations; SRBC

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CD11B ANTIGEN; CD4 ANTIGEN; ETHYLNITROSOUREA; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ANIMAL; ANTIGEN PRESENTING CELL; ARTICLE; BRAIN TUMOR; CELLULAR IMMUNITY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ERYTHROCYTE; FEMALE; GLIOMA; IMMUNOLOGY; MALE; METABOLISM; MICROGLIA; NEWBORN; PATHOLOGY; PHAGOCYTOSIS; PHENOTYPE; RAT; SURVIVAL RATE; ULTRASTRUCTURE;

ANIMALS; ANIMALS, NEWBORN; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11B; ANTIGENS, CD4; BIOLOGICAL RESPONSE MODIFIERS; BRAIN NEOPLASMS; ERYTHROCYTES; ETHYLNITROSOUREA; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MICROGLIA; PHAGOCYTOSIS; PHENOTYPE; RATS; RECEPTORS, INTERLEUKIN-2; SURVIVAL RATE;

EID: 18844422160     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.4.423     Document Type: Article

References (45)

1. Badie B, Sohartner J. Role of microglia in glioma biology. Micnosc ResTech 2001; 54:106-13. (Pubitemid 32645875)
2. Davis EJ, Foster TD, Thomas WE. Cellular forms and functions of brain microglia. Brain Res Bull 1994; 34:73-8. (Pubitemid 24099729)
3. Williams K, Ulvestad E, Antel J. Immune regulatory and effector properties of human adult microglia studies in vitro and in situ. Adv Neuroimmunol. 1994; 4:273-81. (Pubitemid 24325874)
4. Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann Med 2002; 34:491-500. (Pubitemid 36113806)
5. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999; 100:216-32. (Pubitemid 30038255)
6. Maxwell M, Galanopouios T, Neville-Golden. Effect of the expression of transforming growth factor beta2 in primery human glioblastomas on immunosuppression and loss of immunosurveillance. J Neurosurg1992; 76:99-280.
7. Taniguchi Y, Ono K, Yoshida S, Tanaka R. Antigen presenting capability of glial cells under glioma harboring conditions and the effect of glioma derived factors on antigen presentation. J Neuroimmunol 2000; 111:177-85.
8. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002; 40:252-9. (Pubitemid 35337382)
9. Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002; 69:94-103. (Pubitemid 34734169)
10. Aloisi, F, Serafini, B, Adorini, L. Glia-T cell dialogue. J Neuroimmunol. 2000; 107:11.
11. Aliosi F, Simone RD, Columba-Cabezar, et al. Functional maturation of adult resting microglia into an APC is promoted by Granulocyte-Macrophage- Colony-stimulating factor and interaction wit the Th1 cells. J Immunol 2000; 164:1705-12.
12. Aliosi F, Ria F, Columba-Cabezar S, Hess H, Penna G, et al. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naïve CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol1999; 29:2705-14.
13. Fathallah-Shaykh HM, Gao W, Cho M, Herrera MA. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer 1998; 75:266-76. (Pubitemid 28100069)
14. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of TNF-α by microglia and astrocytes in culture. Brain Res 1989; 491:394-7. (Pubitemid 19163393)
15. Gillespie GY, Mahalay MS. Biological response modifier therapies for patient with malignant gliomas. In: G. T. Thomas ed. Neuro-Oncology . Churchill Livingstone: NewYork 1995: p. 242-81.
16. Chaudhuri Swapna, Sinha A, Sengupta A, Chaudhuri S.Sheep erythrocytes provide metabolic triggers for tumor phagocytosis in polymorphonuclear neutrophils:A possible mechanism for tumor inhibition in mice . Biochem Int 1991; 23:231.
17. Chaudhuri S, Dutta SK, Roy RU, Gangopadhyay SK, Chaudhuri S. Immunomodulation and 'Ia' variability in dendritic lymph cells: radiobinding immunoassay versus immune response study. Biochem. Mol Biol Int 1993; 30:471-4.
18. Gangopaddhyay SK, Sarkar S, Begum Z, et al. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen. Ind J Exp Biol 2002; 45:812-5.
19. Druckrey H, Ivancovic S, Preussman R. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature 1966; 210:1378-9.
20. Koestner A, Swenberg JA, Wechsler . Transplacental production with ethylnitrosourea of neoplasms of the nervous system in Sprague -Dawley rats . AMJ Pathol 1971; 63:37-9.
21. Lantos PL. Chemical induction of tumors in the nervous system. In G.T. Thomas ed. Neuro-Oncology. Churchill Livingstone: New York 1993: p. 85-107.
22. Roggendorf W, Strupp S, Paulus W.Distribution and characterisation of microglia/macrophages in human brain tumor. Acta Neuropathol (Berl.) 1996; 92:288-93. (Pubitemid 26278960)
23. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct exvivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol 1995; 154:4309-21.
24. Giulian D, Li J, Bartel S, Broker J, Li X, et al. Cell surface morphology idenfies microglia as a distinct class of mononuclear phagocyte. J Neurosci 1995; 15:7712-26.
25. Badie, B, Schartner, JM. Flowcytometric characteriration of tumor associated macrophages in experimental gliomas. Neurosurg 2000; 46:957.
26. Chaudhuri Swapna, Sarker S, Roy RU, et al. Microglia-the APC of the brain, possess immunocompetent receptors and the excitatory- inhibitory potential to protein kinase activity. The Immunologist 1998; Suppl.1:145.
27. Chaudhuri S, Sinha A, Ghosh AK, Chaudhury S. Surface alterations of peripheral blood lymphocytes from patients with neoplasia: A comparative ultrastructural analysis from patients with benign breast lumps and tuberculosis. Indian J Physiol Allied Sci 1992; 46:24.
28. Hayes GM, Woodroof MN, Cozner ML. Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci 1987; 80:25.
29. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of TNF- by microglia and astrocytes in culture. Brain Res 1989; 491:394-7. (Pubitemid 19163393)
30. Lee YB, Satoh J, Walker DG, Kim SU. Interleukin-15 gene expression in human astrocytes and microglia in culture. Neuroreport 1996; 7:1062-6. (Pubitemid 26194481)
31. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL et al. Cytokine regulation of human microglial cell IL- 8 production. J Immunol 1998; 160:1944-8. (Pubitemid 28106484)
32. Conti B, Park L, Caligasan NY, Kim Y, Kim H, et al. Cultures of astrocytes and microglia express interleukin -18. Mol Brain Res 1999; 67:46-52. (Pubitemid 29170067)
33. Si Q, Nakamura Y, Kataoka K. A serum factor enhances production of nitric oxide and tumor necrosis factor-alpha from cultured microglia. Exp Neurol 2000; 162:89-97. (Pubitemid 30170103)
34. Du ZY, Li XY. Cytokine and nitric oxide production by rat microglia stimulated with lipopolysaccharides in vitro. Chung-Kuo Yao Li Hsueh Pao-Acta Pharmacologica Sinica 1998; 19:257-60.
35. Sakai N, Kaufman S, Milstein S. Parallel induction of nitric oxide and tetrahydrobiopterin synthesis by cytokines in rat glial cells. J Neurochem 1995; 65:895-902.
36. Lockhart BP, Cressey KC, Lepagnol JM. Suppression of nitric oxide formation by tyrosine kinase inhibitors in murine N9 microglia. Br J Pharmacol 1998; 123:879-89. (Pubitemid 28085388)
37. Hellendall RP, Ting JP. Differential regulation of cytokine-induced major histocompatibility complex class II expression and nitric oxide release in rat microglia and astrocytes by effectors of tyrosine kinase, protein kinase C and cAMP. J Neuroimmunol 1997; 74:19-29. (Pubitemid 27128973)
38. Hickey WF, Hsu BL, Kimura H. T-lymphocytes entry into the central nervous system. J Neurosci Res 1991; 28:254.
39. Weller RO, Engelhardt B, Phllips MJ. Lymphocytes targetting of the central nervous system: a review of afferent CNS-immune Pathways. Brain Pathol. .1996; 6(3): 275.
40. Selmaj K. Pathophysiology of the blood-brain barrier. In: Chofflon M, Steinman L. Springer-Verlag eds. Immunoneurology. New York, 1996: p. 175.
41. Bradle M. Immune control of the brain. In: Chofflon M, Steinman L. Immunoneurology. Springer-Verlag: New York, 1996: p.153.
42. Abd-el-Basset EM, Fedoroff S. Effect of bacterial wall lipopolysaccharide (LPS) on morphology, motility and cytoskeletal organization of microglia in cultures. J Neurosci Res 1995; 41:222-37.
43. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Ngatsu T. Interleukin 10 inhibitis both production and expression of cutokine receptors in microglia. J Neurochem 1999; 72:1466-71. (Pubitemid 29140817)
44. Panek RB, Benveniste EN. Class II MHC gene expression in microglia: Regulation by the cytokines IFN- gamma, TNF- alpha and TGF- beta. J Immunol 1995; 154:2846-54.
45. Mukherjee J, Dutta S, Sarkar S, Begum Z, Ghosh ., Chaudhuri S, Chaudhuri S. Preclinical changes in immunereactivity and cellular architecture during the progressive development of intracranial neoplasm and its immunotherapeutic schedule with a novel biological response modifier, the T11TS / S-LFA3. Asian Pacific J Cancer Prev 2002, 3:325-7.